$NVO News

Last published 3d ago

3d agoNVO LLYFDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, ZepboundCNBCThe agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.
4d agoNVO LLY IFFCould supplements be the next big opportunity in the GLP-1 weight-loss drug boom?CNBCNovonesis is exploring whether gut health supplements could benefit patients taking GLP-1 weight-loss drugs, opening up a potentially lucrative new market.
1w agoNVO LLYNovo raises full-year outlook as Wegovy pill sales impressCNBCNovo posted quarterly earnings ahead of expectations early Wednesday as sales of its Wegovy pill blew past estimates
1w agoPNGAF RHHBY NVO VKTX+1Peptide Therapies Are Changing the Future of Medicine — And the Market Could Reach $335 BillionGlobeNewswireNEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Peptide-based treatments are attracting growing attention from major pharmaceutical companies as researchers push into new ways to treat diabetes, obesity, cancer, metabolic
2w agoPNGAF NVO HIMS ENHA+1The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of GrowthGlobeNewswireNEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Peptide-based medicines are becoming a bigger force in the pharmaceutical industry, and the money flowing into this field reflects that shift. Obesity and diabetes
2w agoLLY NVO AZN RHHBYBillions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two DecadesGlobeNewswireDENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — Eli Lilly (NYSE:LLY), Novo Nordisk (NYSE:NVO), AstraZeneca (NYSE:AZN), and Roche (OTCQX:RHHBY) are among the biopharma companies committing billions of
3w agoMRNA NVOOpenAI acquires startup Orchestra Bio⁠ to beef up its biotech businessTechCrunch
3w agoNVONovo's next-generation obesity drug shows 25% weight loss in women in late-stage analysisCNBCNovo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.
1mo agoWMT NVO LLYWalmart to cover some GLP-1s, inhalers and insulin for employees at no cost as it expands benefitsCNBCWalmart will offer Novo's Ozempic and Lilly's Mounjaro without charge for people with Type 2 diabetes after a new prior authorization.
1mo agoANTHR.FG ACN MS NVOAnthropic to invest $100 million to train AI engineer talentCNBCAnthropic will invest $100 million to train nearly 10,000 AI engineers, partnering with a number of consulting firms.
1mo agoLLY NVOWhy Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1sCNBCEli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
1mo agoNVS NVO AZN-GB GSK+3Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar dealsCNBCWestern biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.
1mo agoSBUX US30Y US10Y .SPX+9Yields keep rising, Novo's tough week, why cat product sales are surging and more in Morning SquawkCNBCHere are five key things investors need to know to start the trading day.
1mo agoNVO LLY IHE IHINovo's new strategy hinges on something it can't manufacture: investor trustCNBCNovo has now reached the point where it can broaden its ambitions again, CEO Mike Doustdar told CNBC, but investors remain unconvinced.
1mo agoPSKY INTC AMD QCOM+8Nasdaq's new record, Paramount settles lawsuit, press pool suspends coverage and more in Morning SquawkCNBCHere are five key things investors need to know to start the trading day.
1mo agoLLY NVOEli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugsCNBCThey're the latest metrics on how much the new Medicare coverage is expanding access to GLP-1 medicines since it launched in July.
1mo agoLLY NVOEli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up productionCNBC
1mo agoNVOAnthropic is operating a lab that conducts biology experimentsTechCrunch
1mo agoAAPL RIVN BAR UBS+2Stifel BitsStifel Insights$4.76 billion: U.S. box office ticket sales from May through Labor Day this year, reaching a new record.6.7 million: The expected attendance at this year’s Oktoberfest festivities in Munich.3.4%: The annual August consumer price index inflation rate, with gasoline prices 27.4% higher than a year ago.
1mo ago.IXIC MU NVDA US10Y+4Trump calls AI fears a 'hoax', Treasury yields surge, Moynihan's warning and more in Morning SquawkCNBCHere are five key things investors need to know to start the trading day.
2mo agoNVONovo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market shareCNBCThe Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly.
2mo agoSDZ-CH NVO NVS'Patients pay the tariff': Swiss pharma CEO warns of Trump's generic drug tariff threatCNBCSandoz CEO Richard Saynor warns steep U.S. tariffs on imported generic drugs could force manufacturers to raise prices or cut supply.
2mo agoNVO PFE LLYTrump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakersCNBCThe string of deals builds on the Trump administration's push to link the nation's drug prices to cheaper ones abroad.
2mo agoCNXU LLY NVO ABBV+1A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.GlobeNewswireIssued on behalf of Conexeu Sciences Inc. NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - For as long as aesthetic medicine has existed, its central promise has been to replace what time
3mo agoNVO LLYNovo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition has to be fair'CNBCNovo Nordisk CEO defended the company's decision to sue rival Eli Lilly over its weight-loss drug advertising.
3mo agoNVO LLY XLPEli Lilly takes weight-loss pill battle global with first Foundayo approval outside U.S.CNBCLilly's Foundayo wins U.K. approval, taking its weight-loss pill battle with Novo Nordisk's Wegovy beyond the U.S. market.
3mo agoNVO LLYEli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surgeCNBCEli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion.
3mo agoNVO LLYNovo Nordisk's raised forecast fails to change the debate over its obesity businessCNBCWall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
3mo agoNVO LLYNovo Nordisk shares slide after guidance disappoints investorsCNBCNovo Nordisk raised its financial outlook as it tries to catch up with rival Eli Lilly in the booming GLP-1 market.
3mo agoNVONovo Nordisk shares dive after heart medicine fails trialCNBCThe experimental medicine ziltivekimab didn't translate into a statistically meaningful reduction in major cardiovascular adverse events, Novo said Friday.
3mo agoNVO LLYWhy shareholders are suing Novo Nordisk over next-generation weight-loss drugCNBCInvestors claim Novo Nordisk misled the market about CagriSema's tolerability, after disappointing clinical trial results wiped billions off its market cap.
3mo agoCHRW DHL-DE UPS FDX+2Logistics giants are racing to keep up with healthcare boom as GLP-1s highlight need for cold storageCNBCShipping and logistics companies are tapping into the growing market of healthcare as cold chain and temperature-controlled facilities become more crucial.
3mo agoLLY PFE NVOTrump plans generic drug tariffs from 2028 with two-year delay testing U.S. onshoring pushCNBCThe latest tariff salvo underscored Trump's goal of reshoring low-cost drug production, but displacing established suppliers like India won't be easy.
3mo agoNVO LLYNovo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertisingCNBCNovo asked the court to permanently stop Lilly from running the "deceptive" ads and require the drugmaker to issue corrective advertising.
3mo agoNES.N-CH NVO LLY CL+5Fat cat? Weight-loss drugs may be coming for your overweight petCNBCStartups are testing GLP-1 treatments for overweight cats while pet-food giants are leaning into longevity products as owners spend more on animal health.
4mo agoCNXU ABBV NVO EOLS+2One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical AestheticsPR NewswireIn regenerative medicine, the durable advantage rarely comes from a single product; it comes from a platform that can be pointed at more than one...
4mo agoLLY NVOHealthy Returns: Employers aren't expanding coverage of GLP-1 obesity drugs – many are finding ways around itCNBCAround 36% of employers said they provide coverage of GLP-1s for both diabetes and weight loss, the same as 2025 and up from 34% in 2024, the survey said.
4mo agoCNXU ABBV LLY NVOA $190 Billion Weight-Loss Boom Exposed a Tissue-Restoration Gap, and One Nasdaq Company Is Moving to Fill ItPR NewswireEquity Insider News Commentary, The weight-loss drug boom is one of the defining medical stories of the decade, and its second-order effects are only ...
4mo agoWMT CVS NVO LLYHealthy Returns: Walmart, CVS step in to help seniors navigate Medicare coverage of obesity drugsCNBCMedicare has started covering obesity drugs for the first time – and companies like Walmart and CVS Health are playing an important role for patients.
4mo agoAMGN MRNA TMO NVOAnthropic’s Claude Science bets on workflow, not a new model, to win over scientistsTechCrunch
4mo ago.DJI .RUT .SPX .IXIC+9SCOTUS decisions, Dow at 52,000, the retirement savings gap and more in Morning SquawkCNBCHere are five key things investors need to know to start the trading day.
4mo agoUPS NVOUPS to invest $48 million in temperature-controlled facilities amid healthcare boomCNBCUPS is announcing a new investment in healthcare logistics as demand for the temperature-controlled category booms, CNBC has learned exclusively.
4mo agoBIRD GME NVO HPE+1The CEO of Allbirds’ new AI biz has a plan, but no employeesTechCrunch
4mo agoROP-CH NVO LLYZealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmakerCNBCWhile the market's enthusiasm for one of Zealand's experimental drugs has cooled, investors are shifting focus to amylin-based medicines as a growth driver
5mo agoAZN NVO ZLDPF ROP-CH+3Drugmakers race to find a place in the next wave of obesity drugsCNBCDrugmakers are betting they can crack into the obesity drug market that Novo Nordisk and Eli Lilly currently dominate.
5mo agoNVO LLY HUMNovo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverageCNBCNovo Nordisk and Eli Lilly bring their longtime rivalry to GLP-1 pills and prepare to make their pitch to seniors with Medicare.
5mo agoDXCM GOOGL NVO LLY+1Signos grows foothold in weight-loss wave fueled by GLP-1s with its AI health data trackingCNBCHealth tech startup Signos announced a $20 million funding round Wednesday, including an expanded partnership with medical device giant Dexcom.
5mo agoDJT HIMS LLY MMA+2Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness MarketsGlobeNewswireNEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The market for peptide-based health and performance products has been growing fast as more consumers focus on fitness, recovery, longevity, weight management, and overall wellness.
5mo agoLLY NVOWhite House adds generic drugs to direct-to-consumer TrumpRx siteCNBCTrump said he is increasing the number of products on the platform by nearly seven times, adding more than 600 generic drugs to the site.
6mo agoHIMS NVO MNKD DNAThe $59B Quiet Shift Reshaping How Patients Access CarePR NewswirePoint-of-care diagnostics just crossed $58.76 billion globally in 2026, growing at nearly 10% annually as testing that used to require a hospital lab ...